Front-line daratumumab-VTd versus standard-of-care in ASCT-eligible multiple myeloma: matching-adjusted indirect comparison.
暂无分享，去创建一个
H. Goldschmidt | P. Sonneveld | P. Moreau | X. Leleu | M. Merz | T. Facon | S. Krotneva | U. Bertsch | H. Salwender | E. Mai | L. Benboubker | C. Hulin | S. Zweegman | D. Caillot | K. Weisel | I. Proskorovsky | B. Hébraud | A. Lam | M. Hashim | Jianming He | S. Côté | Charlene Lee | T. Kampfenkel | V. Vanquickelberghe | C. Boer | Yannan Hu